低风险前列腺癌与甲状腺癌的相似之处:一篇综述
本综述比较低风险前列腺癌与甲状腺癌在筛查、诊断、风险分层及主动监测方面的异同。两者均存在惰性亚临床 reservoir,但预期寿命与治疗 sequelae 不同,可能最终导致不同的管理范式。前列腺癌试验经验可为甲状腺癌管理提供模型,可能重塑主动监测为可信、有价值的治疗方式。
要点
- 美国预防服务工作组对前列腺特异性抗原检测或颈部超声筛查发出谨慎推荐,活检阈值已提高。
- 前列腺癌长期随机前瞻性临床试验已确立主动监测为适当分层低风险患者的一线治疗。
- 甲状腺癌观察性试验在定义手术风险与资格方面取得进展,但患者更年轻、手术更安全,监测门槛可能更高。
核心结论
- 尽管低风险前列腺癌与甲状腺癌在生物学惰性上相似,但预期寿命和治疗 sequelae 的关键区别可能最终赋予两种疾病不同的管理范式。
- 前列腺癌试验的经验可作为甲状腺癌管理的模型,可能将主动监测重塑为可信、有价值的治疗方式。
研究设计与样本
- 本综述比较低风险前列腺癌与甲状腺癌在筛查、诊断、风险分层和主动监测考虑方面的异同。
主要发现
- 许多国家观察到甲状腺癌发病率快速上升,但该激增仍低估了疾病的真实范围。
- 大多数新诊断甲状腺癌为偶然发现的小、低风险癌症,不太可能造成伤害。
- 前列腺癌同样具有行为良好的亚临床 reservoir、长自然史和极佳结局,使主动监测成为低风险疾病事实上的指南推荐。
- 前列腺癌和甲状腺癌均经历了重新校准的去升级转变,以应对变化的流行病学格局。
- 美国预防服务工作组对通过前列腺特异性抗原检测或颈部超声筛查发出谨慎推荐,同时进行活检的阈值已提高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要深入研究的 caveats 包括老年患者的侵袭性疾病、疾病范围的低估以及共享决策中的医患偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Across many countries, a rapid escalation of the incidence of thyroid cancer has been observed, a surge that nonetheless underestimates the true extent of the disease. Most thyroid cancers now diagnosed comprise small, low-risk cancers that are incidentally found and are unlikely to cause harm. In many ways, prostate cancer similarly harbors a well-behaved subclinical reservoir, a long natural history, and superlative outcomes that have made active surveillance the de facto guideline recommendation for low-risk disease. This review highlights the parallels and differences between prostate cancer and thyroid cancer regarding screening, diagnosis, risk stratification, and considerations for active surveillance. OBSERVATIONS: Prostate cancer and thyroid cancer have undergone recalibrated, de-escalatory shifts to counter changing epidemiologic landscapes. The US Preventive Services Task Force has issued cautionary recommendations on screening via prostate-specific antigen testing or neck ultrasonography, while the thresholds to performing biopsy have increased. Comparable changes to cancer terminology and staging have also helped alleviate patient anxiety and minimize pressure for overtreatment. Long-term, randomized prospective clinical trials for prostate cancer have established active surveillance as a first-line treatment approach for properly stratified low-risk patients, while observational trials for thyroid cancer have also made strides in defining risk and eligibility for surgery. Caveats requiring deeper investigation include aggressive disease in older patients, underestimation of the extent of the disease, and patient-physician bias in shared decision making. For prostate cancer, survival may not improve and function will likely worsen after intervention; for thyroid cancer, patients are younger, surgery is safer, and the bar for surveillance will likely be higher. CONCLUSIONS AND RELEVANCE: Despite similarities in biological indolence between low-risk prostate and thyroid malignant neoplasms, key distinctions in life expectancy and treatment sequelae may ultimately confer somewhat disparate management paradigms for the 2 diseases. Nevertheless, the experience forged by prostate cancer trials serves as a model for thyroid cancer management, potentially reshaping the perception of active surveillance into a credible, valuable treatment modality.
引用
- Ho AS, Daskivich TJ, Sacks WL, et al. Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer: A Review. JAMA Oncol. 2019. PMID: 30543358. doi:10.1001/jamaoncol.2018.5321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。